Meridian Bioscience EBIT

Meridian Bioscience (VIVO) currently reports a EBIT of $26M as of December 2022. That compares with $84M in the prior-year period — down 68.8% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Meridian Bioscience's EBIT history and peer comparisons.

Meridian Bioscience's EBIT decreased from $84M to $26M — a 68.8% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Meridian Bioscience's EBIT of $26M is lower than the Healthcare sector average of $22B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Meridian Bioscience reported $26M in EBIT as of December 2022. That compares with $84M in the prior-year period — down 68.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Meridian Bioscience, and consider following VIVO for alerts when major investors trade the stock.